Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + Irinotecan + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Temozolomide||Temodar||Methazolastone||Chemotherapy - Alkylating 14||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||neuroblastoma||no benefit||Bevacizumab + Irinotecan + Temozolomide||Phase II||Actionable||In a Phase II trial, treatment with Temodar (temozolomide), Camptosaur (irinotecan), and Avastin (bevacizumab) in combination did not demonstrate benefit over data for Temodar (temozolomide) and Camptosaur (irinotecan) combination therapy, resulting in complete response in 9% (3/33), no response in 55% (18/33), and progressive disease in 36% (12/33) of patients with refractory or relapsed neuroblastoma (PMID: 28111925; NCT01114555).||28111925|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01217437||Phase II||Irinotecan + Temozolomide Bevacizumab + Irinotecan + Temozolomide||Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors||Active, not recruiting|
|NCT00876993||Phase I||Bevacizumab + Irinotecan + Temozolomide||Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors||Completed|
|NCT01189643||Phase I||Bevacizumab + Irinotecan + Temozolomide||Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor||Active, not recruiting|